These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 16204287)

  • 21. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib RP; Nascimento P; Pastores GM
    Cochrane Database Syst Rev; 2013 Feb; (2):CD006663. PubMed ID: 23450571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.
    Germain DP; Waldek S; Banikazemi M; Bushinsky DA; Charrow J; Desnick RJ; Lee P; Loew T; Vedder AC; Abichandani R; Wilcox WR; Guffon N
    J Am Soc Nephrol; 2007 May; 18(5):1547-57. PubMed ID: 17409312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
    Sasa H; Nagao M; Kino K
    Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
    Tahir H; Jackson LL; Warnock DG
    J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
    Vedder AC; Linthorst GE; Houge G; Groener JE; Ormel EE; Bouma BJ; Aerts JM; Hirth A; Hollak CE
    PLoS One; 2007 Jul; 2(7):e598. PubMed ID: 17622343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study.
    Eto Y; Ohashi T; Utsunomiya Y; Fujiwara M; Mizuno A; Inui K; Sakai N; Kitagawa T; Suzuki Y; Mochizuki S; Kawakami M; Hosoya T; Owada M; Sakuraba H; Saito H
    J Inherit Metab Dis; 2005; 28(4):575-83. PubMed ID: 15902561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
    Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
    J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process.
    Khan A; Sirrs SM; Bichet DG; Morel CF; Tocoian A; Lan L; West ML;
    Drugs R D; 2021 Dec; 21(4):385-397. PubMed ID: 34542871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
    Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
    J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib RP; Pastores GM
    Cochrane Database Syst Rev; 2010 May; (5):CD006663. PubMed ID: 20464743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spotlight on agalsidase beta in Fabry disease.
    Keating GM; Simpson D
    BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
    Thurberg BL; Rennke H; Colvin RB; Dikman S; Gordon RE; Collins AB; Desnick RJ; O'Callaghan M
    Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
    Feriozzi S; Torras J; Cybulla M; Nicholls K; Sunder-Plassmann G; West M;
    Clin J Am Soc Nephrol; 2012 Jan; 7(1):60-9. PubMed ID: 22246281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
    Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
    Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.
    Weidemann F; Krämer J; Duning T; Lenders M; Canaan-Kühl S; Krebs A; Guerrero González H; Sommer C; Üçeyler N; Niemann M; Störk S; Schelleckes M; Reiermann S; Stypmann J; Brand SM; Wanner C; Brand E
    J Am Soc Nephrol; 2014 Apr; 25(4):837-49. PubMed ID: 24556354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.